AL amyloidosis

A plasma cell disorder characterized by the aggregation and deposition of insoluble amyloid fibrils derived from misfolding of monoclonal immunoglobulin light chains usually produced by a plasma cell tumor. It usually presents as primary systemic amyloidosis (PSA) with multiple organ involvement and less frequently as primary localized amyloidosis (PLA) restricted to a single organ.

Anemia

A reduction in erythrocytes volume or hemoglobin concentration.


Total: 2

                       


(per page)
PMID (PMCID)
30477388
 FEMALE Adult
Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR, Usmani SZ, Adamu H, Mishkin J, Bhutani M.
J Oncol Pharm Pract. 2019;25(4):1021-1025.
A 43-year-old female with light-chain amyloidosis and concomitant multiple myeloma presented with severe bowel dysmotility causing abdominal pain, anemia, and a 100-pound unintentional weight loss.
20139056
 MALE
Systemic amyloidosis presenting as mucocutaneous bullous lesions.
Ahmad QM, Sultan SJ, Shah IH, Sameem F.
Hematol Oncol Stem Cell Ther. 2009;2(3):418-21.
Examination and tests in this patient also revealed anemia, hepatomegaly, infiltrative cardiomyopathy, polyneuropathy and immunoglobulin l deposition, favoring a diagnosis of primary amyloidosis (AL type).